Literature DB >> 31522196

Polish version of the Self-evaluation of Negative Symptoms (SNS).

Paweł Wójciak1, Krystyna Górna2, Klaudia Domowicz1, Krystyna Jaracz3, Renata Szpalik2, Michał Michalak4, Janusz Rybakowski1.   

Abstract

OBJECTIVES: The aim of the study was to create a Polish version of the Self-evaluation of NegativeSymptoms (SNS) scale, to assess its internal consistency, and to make correlations between the SNS scores and the Brief Negative Symptom Scale (BNSS) scores in the group of patients with schizophrenia.
MATERIAL AND METHODS: The procedure of Polish adaptation of the French-language version of the SNS scale, comprising 20 items organized in 5 subscales: asociality, blunted affect, alogia, avolition and anhedonia, was carried out. Psychometric tests were performed in 40 patients with paranoid schizophrenia (20 men and 20 women) with severity of symptoms on the Positive and Negative Syndrome Scale (PANSS) 56±16 points, receiving unchanged pharmacological treatment in the last 3 months.
RESULTS: The Polish version of the SNS scale was accepted by the author of the scale, Professor Sonia Dollfus. The reliability analysis showed high values of the Cronbach's alpha coefficient for the whole scale (0.91) and for the subscales (0.61-0.85). The SNS and its subscales showed significant correlations with the total BNSS score and with the scores of the BNSS subscales, which confirms the validity of the scale.
CONCLUSIONS: A statistically significant level of consistency of the whole scale and its individual domains with the results of the clinical assessment with the BNSS, speaks for the adequacy of the self - assessment of negative symptoms by a patient with schizophrenia. Good psychometric properties of the Polish version of the SNS obtained in the study can indicate its usefulness in the research on negative symptoms conducted in Poland.

Entities:  

Keywords:  Self-evaluation of Negative Symptoms; negative symptoms; schizophrenia

Mesh:

Year:  2019        PMID: 31522196     DOI: 10.12740/PP/OnlineFirst/97352

Source DB:  PubMed          Journal:  Psychiatr Pol        ISSN: 0033-2674            Impact factor:   1.657


  5 in total

1.  Validation of the Arabic version of the "self-evaluation of negative symptoms" scale (SNS).

Authors:  Aline Hajj; Souheil Hallit; Karam Chamoun; Hala Sacre; Sahar Obeid; Chadia Haddad; Sonia Dollfus; Lydia Rabbaa Khabbaz
Journal:  BMC Psychiatry       Date:  2020-05-14       Impact factor: 3.630

2.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

3.  Association of Negative Symptoms of Schizophrenia Assessed by the BNSS and SNS Scales With Neuropsychological Performance: A Gender Effect.

Authors:  Paweł Wójciak; Klaudia Domowicz; Marta Zabłocka; Michał Michalak; Janusz K Rybakowski
Journal:  Front Psychiatry       Date:  2021-12-24       Impact factor: 4.157

4.  European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study.

Authors:  Sonia Dollfus; Armida Mucci; Giulia M Giordano; István Bitter; Stephen F Austin; Camille Delouche; Andreas Erfurth; W Wolfgang Fleischhacker; Larisa Movina; Birte Glenthøj; Karoline Gütter; Alex Hofer; Jan Hubenak; Stefan Kaiser; Jan Libiger; Ingrid Melle; Mette Ø Nielsen; Oleg Papsuev; Janusz K Rybakowski; Gabriele Sachs; Alp Üçok; Francesco Brando; Pawel Wojciak; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2022-01-31       Impact factor: 4.157

5.  The Deficit Schizophrenia Subtype Is Associated with Low Adherence to the Mediterranean Diet: Findings from a Case-Control Study.

Authors:  Krzysztof Kowalski; Bogna Bogudzińska; Bartłomiej Stańczykiewicz; Patryk Piotrowski; Tomasz Bielawski; Jerzy Samochowiec; Krzysztof Szczygieł; Piotr Plichta; Błażej Misiak
Journal:  J Clin Med       Date:  2022-01-23       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.